中国P站

Atherosclerosis is a chronic vascular disease characterized by the accumulation of lipid-rich plaques within the arterial walls, leading to progressive narrowing and impaired blood flow. It is a major contributor to cardiovascular diseases, including coronary artery disease, stroke, and peripheral artery disease, and remains a leading cause of morbidity and mortality worldwide. At the heart of atherosclerosis lies endothelial dysfunction a condition wherein the endothelium loses its ability to regulate vascular tone, inflammatory responses, and thrombotic balance. Endothelial dysfunction plays a pivotal role in the initiation and progression of atherosclerosis by promoting inflammation, oxidative stress, and vascular stiffness, making it a key target for therapeutic intervention. Traditional treatment strategies focus on lipid-lowering therapies, antihypertensive medications, and lifestyle modifications; however, emerging research underscores the need for novel approaches that specifically target endothelial dysfunction to mitigate the disease process more effectively [1].

Description

Over the past few decades, considerable advancements have been made in understanding the molecular mechanisms underlying endothelial dysfunction, leading to the development of promising therapeutic strategies aimed at restoring endothelial homeostasis. These interventions range from pharmacological agents designed to enhance nitric oxide bioavailability and reduce oxidative stress to regenerative therapies utilizing stem cells and gene-editing technologies [2]. Dietary interventions and nanotechnology-based drug delivery systems have also emerged as promising approaches for improving endothelial function and preventing the progression of atherosclerosis. The growing body of evidence supporting these novel therapeutic strategies highlights the potential for more precise and effective treatments that address endothelial dysfunction at its core. This manuscript explores these innovative approaches, providing a detailed description of their mechanisms, effectiveness, and potential for clinical application [2].

One of the most extensively studied novel therapeutic strategies targeting endothelial dysfunction in atherosclerosis is the enhancement of nitric oxide (NO) signaling. NO, a key vasodilatory molecule produced by endothelial cells, plays a critical role in maintaining vascular homeostasis by preventing platelet aggregation, reducing inflammation, and improving endothelial cell survival [3]. Reduced NO bioavailability is a hallmark of endothelial dysfunction, largely driven by oxidative stress and the upregulation of inflammatory pathways. To address this, various pharmacological agents, such as statins, angiotensin-converting enzyme inhibitors, and phosphodiesterase-5 inhibitors, have been explored for their ability to enhance NO production and reduce oxidative stress. More recently, endothelial-targeted gene therapy approaches using inducible nitric oxide synthase (iNOS) or endothelial nitric oxide synthase (eNOS) gene delivery have emerged as promising avenues for restoring endothelial function and reversing disease progression [4].

Beyond NO-based therapies, stem cell and regenerative medicine approaches are gaining attention as potential solutions to endothelial dysfunction. Endothelial progenitor cells (EPCs), derived from bone marrow and circulating in the bloodstream, play a vital role in vascular repair and regeneration. Studies have demonstrated that transplanting EPCs into atherosclerotic arteries can enhance endothelial function by promoting re-endothelialization and reducing inflammation [5]. Mesenchymal stem cells (MSCs) have also shown promise in modulating endothelial repair through their paracrine signaling effects, including the secretion of anti-inflammatory cytokines and growth factors. Exosome-based therapies derived from MSCs and EPCs are an emerging area of interest, as these small extracellular vesicles carry bioactive molecules that promote endothelial healing and reduce vascular inflammation [6].

Nanotechnology is revolutionizing drug delivery for endothelial dysfunction in atherosclerosis by enabling targeted delivery of therapeutic agents to diseased endothelial cells. Nanoparticles, liposomes, and nanocarriers loaded with antioxidants, anti-inflammatory molecules, or gene-editing tools offer a precise method for modulating endothelial function without systemic side effects. Notably, nanoparticles designed to deliver NO donors directly to dysfunctional endothelium can enhance vasodilation and inhibit plaque formation. Similarly, CRISPR/Cas9-based gene editing using nano-delivery systems allows for precise modifications of endothelial genes implicated in atherosclerosis, opening new doors for personalized therapy [7].

Dietary and lifestyle interventions remain a fundamental aspect of endothelial health, but recent research highlights specific nutraceuticals and bioactive compounds that can directly modulate endothelial function at the molecular level. Polyphenols, found in berries, green tea, and dark chocolate, exert antioxidant effects and improve NO production. Omega-3 fatty acids, abundant in fish oil, reduce endothelial inflammation and enhance cell membrane integrity. Additionally, probiotics targeting gut microbiota have emerged as novel modulators of endothelial function, influencing vascular health through microbial metabolites and immune regulation [8].

Conclusion

The treatment of endothelial dysfunction in atherosclerosis is evolving beyond conventional pharmacotherapy toward more precise and targeted approaches. The development of therapies that enhance nitric oxide bioavailability, harness stem cell regenerative potential, and utilize nanotechnology-based drug delivery systems has opened new frontiers in cardiovascular medicine. Moreover, dietary interventions and gene-editing technologies offer promising avenues for personalized and preventive care. The collective advancements in these novel therapeutic strategies highlight the importance of addressing endothelial dysfunction as a fundamental aspect of atherosclerosis treatment rather than merely focusing on lipid regulation and arterial plaque reduction.

Future research will need to focus on optimizing the safety, efficacy, and accessibility of these emerging therapies to ensure their successful translation into clinical practice. As the field of vascular medicine continues to advance, integrating multidisciplinary approaches that combine pharmacology, regenerative medicine, and biotechnology will be essential in developing comprehensive strategies for endothelial dysfunction in atherosclerosis. By targeting the underlying endothelial pathology, these novel therapeutic interventions hold the potential to significantly reduce the burden of cardiovascular diseases and improve patient outcomes worldwide.

Acknowledgement

None

Conflict of Interest

None

References

1. NCD Risk Factor Collaboration (2016) Lancet 387: 1377-1396.

   , ,

2. González-Muniesa P, Mártinez-González MA, Hu FB, Després JP, Matsuzawa Y, et al. (2017) Nat Rev Dis Primers 3: 17034

   , ,

3. Cornier MA, Marshall JA, Hill JO, Maahs DM, Eckel RH (2011) Circulation 124: 840-850.

   , ,

4. Emerging Risk Factors Collaboration (2011) Lancet 377: 1085-1095.

   , ,

5. NCD Risk Factor Collaboration (2017) Lancet 390: 2627-2642

   , ,

6. Amed S, Islam N, Sutherland J, Reimer K (2018) Pediatr Diabetes 19: 630-636.

   , ,

7. Ayer J, Charakida M, Deanfield JE, Celermajer DS (2015) Eur Heart J 36: 1371-1376.

   , ,

8. McGill Jr HC, McMahan CA, Gidding SS (2008) Circulation 117: 1216-1227.

   , ,